10x Genomics, Inc.11

10x Genomics, Inc.

9.53USDR
+0.19+2.09%
At close at May 30, 23:19 GMT
USD
No trades
See on Supercharts

TXG fundamentals

Key facts

Market capitalization‪1.19 B‬USD
Basic EPS (TTM)−1.30USD
Founded2012
Employees (FY)‪1.31 K‬
CEOSerge Saxonov
About

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Ownership
‪‪111.09 M‬‬
Free Float shares
‪‪103.44 M‬‬ (93.11%)
Closely held shares
‪‪7.65 M‬‬ (6.89%)
Free Float shares
‪‪103.44 M‬‬ (93.11%)
Closely held shares
‪‪7.65 M‬‬ (6.89%)
Capital structure
Market cap
‪‪1.19 B‬‬
Debt
‪‪80.07 M‬‬
Cash & equivalents
‪‪426.90 M‬‬
Enterprise value
‪‪842.99 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪1.19 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.83x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
1.83x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−44%‬
‪−38%‬
‪−32%‬
‪−26%‬
‪−20%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Consumables
Instruments
Services
By country
Period: 2024
United States
Europe, Middle East and Africa
China
Asia Pacific (excluding China)
Americas (excluding United States)

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪0.00‬
‪‪45.00 M‬‬
‪‪90.00 M‬‬
‪‪135.00 M‬‬
‪‪180.00 M‬‬
Actual
Estimate
Earnings
Next:Jul 31, 2025
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
‪−0.48‬
‪−0.36‬
‪−0.24‬
‪−0.12‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
TXG has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−150.00 M‬‬
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪150.00 M‬‬
‪‪300.00 M‬‬
‪‪450.00 M‬‬
‪‪600.00 M‬‬
Assets
Liabilities